Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 26, 2017

DrugPatentWatch Database Preview

Nevirapine - Generic Drug Details

« Back to Dashboard

What are the generic sources for nevirapine and what is the scope of patent protection?

is the generic ingredient in three branded drugs marketed by Aurobindo, Sandoz Inc, Aurobindo Pharma Ltd, Alvogen Malta, Apotex Inc, Mylan Pharms Inc, Boehringer Ingelheim, Prinston Inc, Cipla Ltd, Cipla, Mylan Labs, Sciegen Pharms Inc, Micro Labs Ltd, Hetero Labs Ltd Iii, and Strides Pharma, and is included in twenty-two NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Nevirapine has thirty patent family members in twenty-seven countries.

There are twenty drug master file entries for nevirapine. Twenty suppliers are listed for this compound. There are seven tentative approvals for this compound.

Summary for Generic Name: nevirapine

Drug Master File Entries: see list20
Suppliers / Packagers: see list20
Bulk Api Vendors: see list77
Clinical Trials: see list47
Patent Applications: see list5,599
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:nevirapine at DailyMed

Tentative approvals for NEVIRAPINE

Applicant Application No. Form Dosage
► Subscribe► SubscribeTABLET; ORAL50MG
► Subscribe► SubscribeTABLET; ORAL200MG
► Subscribe► SubscribeTABLET; ORAL200MG
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hetero Labs Ltd Iii
TABLET;ORAL078584-001May 22, 2012ABRXNoNo► Subscribe► Subscribe
Mylan Labs
TABLET;ORAL078864-001May 22, 2012ABRXNoNo► Subscribe► Subscribe
Mylan Pharms Inc
TABLET, EXTENDED RELEASE;ORAL205651-001Oct 27, 2014ABRXNoNo► Subscribe► Subscribe
Alvogen Malta
TABLET, EXTENDED RELEASE;ORAL204621-001Jul 10, 2015ABRXNoNo► Subscribe► Subscribe
Alvogen Malta
TABLET, EXTENDED RELEASE;ORAL204621-002Nov 9, 2015ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Predict branded drug patent expiration
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus